Emil Kakkis Net Worth has become a widely searched topic as investors and biotech followers look closely at the financial standing of Emil D. Kakkis. As the founder, CEO, and President of Ultragenyx Pharmaceutical Inc., Dr. Kakkis has built a strong reputation in the rare disease biotechnology sector. His leadership, insider ownership, and executive compensation all play a major role in shaping his overall wealth profile.
With an estimated net worth of over $13 million in 2025, Emil Kakkis’ financial position is closely tied to his stock holdings in Ultragenyx Pharmaceutical. In this article, we explore Emil Kakkis Net Worth, salary, insider trading activity, ownership reports, and company overview to provide a complete and detailed financial breakdown.
Emil D. Kakkis Bio Table
| Full Name | Emil D. Kakkis |
| Known For | Founder, CEO & President of Ultragenyx Pharmaceutical Inc. |
| Profession | Physician-Scientist, Biotech Executive |
| Age (2025) | 64 Years Old |
| Nationality | American |
| Education | Pomona College (Magna Cum Laude); M.D. & Ph.D., UCLA Medical Scientist Program |
| Board Certification | Pediatrics & Medical Genetics |
| Current Position | CEO, President & Director – Ultragenyx Pharmaceutical |
| Founded Ultragenyx | 2010 |
| Estimated Net Worth (2025) | $13.17 Million+ |
| Annual Salary | $1,460,000 |
| Shares Owned | 641,731 shares of Ultragenyx Pharmaceutical |
| Industry | Biotechnology / Rare Genetic Diseases |
| Corporate Address | 60 Leveroni Court, Novato, CA 94949 |
Emil Kakkis Biography and Net Worth
Emil D. Kakkis is a physician-scientist and biotech entrepreneur best known as the founder, CEO, and President of Ultragenyx Pharmaceutical Inc.. He established the company in 2010 with a mission to transform how therapies are developed for rare and ultra-rare genetic diseases. His leadership model focuses on patient-centered innovation and regulatory reform. This visionary approach has shaped both his career and financial success.
When discussing Emil Kakkis Net Worth, most of his wealth comes from equity ownership in Ultragenyx Pharmaceutical. As a long-serving CEO and director, he holds substantial company shares. In addition to stock holdings, he earns executive compensation tied to company performance. His financial growth reflects decades of leadership in rare disease biotechnology.
What is Emil D. Kakkis’ net worth?
As of March 3, 2025, Emil Kakkis Net Worth is estimated to be at least $13.17 million. This valuation is largely based on his ownership of 641,731 shares of Ultragenyx Pharmaceutical stock. The shares were valued at approximately $13,168,320 as of mid-February 2025. This figure does not include any private investments or additional assets he may own.
The majority of Emil D. Kakkis’ net worth is directly tied to his insider ownership in Ultragenyx. As company performance fluctuates, so does the market value of his holdings. His equity position demonstrates long-term confidence in the company he founded. Stock ownership remains the primary driver behind his reported wealth.
How old is Emil D. Kakkis?
Emil D. Kakkis is currently 64 years old as of 2025. Despite his age, he remains actively involved in corporate leadership and strategic planning at Ultragenyx Pharmaceutical. His decades of experience in genetics and pediatrics continue to influence company innovation. Age has strengthened his reputation as a seasoned biotech executive.
Within Ultragenyx Pharmaceutical’s leadership team, he is among the senior executives guiding long-term growth. His background in medical genetics and clinical development provides a strong foundation for decision-making. Over the years, he has combined scientific expertise with executive leadership. This balance has been key to both his professional and financial achievements.
What is Emil D. Kakkis’ salary?
As CEO of Ultragenyx Pharmaceutical Inc., Emil D. Kakkis earns an annual salary of $1,460,000. This executive compensation reflects his responsibilities in overseeing research, regulatory strategy, and commercialization efforts. His salary forms a significant component of Emil Kakkis Net Worth. It also aligns with compensation standards in the biotechnology industry.
In addition to base salary, executive packages often include bonuses, stock awards, and performance incentives. While public disclosures primarily highlight his base pay, total compensation may vary annually. His earnings mirror the scale and complexity of leading a publicly traded biotech company. Leadership performance directly impacts both salary growth and shareholder value.
How do I contact Emil D. Kakkis?
The corporate mailing address for Emil D. Kakkis and Ultragenyx Pharmaceutical executives is 60 Leveroni Court, Novato, California 94949. Investors and stakeholders may reach the company via phone at (415) 483-8800. Official communication can also be directed through email at ir@ultragenyx.com. Most correspondence is handled through investor relations channels.
Direct personal contact with the CEO is typically managed through corporate offices. As a public company executive, inquiries often pass through official departments. Shareholders seeking information about Emil Kakkis Net Worth or insider activity should refer to SEC filings. Public disclosures provide transparent updates on executive compensation and stock ownership.
Has Emil D. Kakkis been buying or selling shares of Ultragenyx Pharmaceutical?
Emil D. Kakkis has not been actively trading shares of Ultragenyx Pharmaceutical in the past ninety days. This indicates a period of holding rather than frequent insider transactions. His long-term ownership reflects confidence in the company’s strategic direction. Stability in insider activity often signals executive commitment.
Over longer timeframes, insider transactions are disclosed through regulatory filings. These records provide transparency into buying and selling patterns. Investors monitoring Emil Kakkis Net Worth often track these disclosures closely. Insider activity can influence market perception and shareholder decisions.
Also Like To Read This Post: Gina Kimmel Net Worth
Who are Ultragenyx Pharmaceutical’s active insiders?
Ultragenyx Pharmaceutical’s active insiders include executive leaders and board members who play vital roles in corporate governance. Among them are CEO Emil Kakkis, CFO Mardi Dier, and other senior executives overseeing medical, financial, and operational divisions. Directors such as William Aliski and Clay Siegall also contribute to oversight. Insider leadership shapes company policy and innovation.
These insiders collectively hold approximately 5.5% ownership in the company. Active insiders are required to report stock transactions publicly. Their decisions often provide insight into corporate confidence and strategy. Monitoring insider rosters helps investors better understand executive influence within Ultragenyx.
Are insiders buying or selling shares of Ultragenyx Pharmaceutical?
During the last twelve months, insiders at Ultragenyx Pharmaceutical sold shares 16 times. A total of 144,493 shares were sold, valued at more than $5.89 million. The most recent recorded transaction involved CFO Howard Horn selling shares in early February. Such activity is disclosed in compliance with securities regulations.
While insider selling can raise investor curiosity, it does not automatically signal negative performance. Executives may sell shares for diversification or personal financial planning. Overall insider ownership remains significant at 5.5% of the company. This continued stake demonstrates sustained executive involvement in corporate growth.
Emil D. Kakkis Insider Trading History at Ultragenyx Pharmaceutical
Emil D. Kakkis has maintained a relatively stable insider trading history at Ultragenyx Pharmaceutical Inc.. Public filings show that while other executives have reported transactions, Dr. Kakkis has not been highly active in short-term trading. His insider activity mainly reflects long-term ownership rather than frequent buying and selling. This consistency aligns with his role as founder and strategic leader.
Investors tracking Emil Kakkis Net Worth often analyze insider trading reports for transparency. Form 4 filings submitted to the SEC provide details of any stock movement. Over recent months, there has been no significant shift in his ownership position. His steady holding pattern reinforces confidence in Ultragenyx’s long-term growth strategy.
Emil D. Kakkis Buying and Selling Activity at Ultragenyx Pharmaceutical
Emil D. Kakkis’ buying and selling activity has been limited in the past ninety days. Unlike some executives who periodically adjust holdings, he has largely retained his shares. This suggests a commitment to maintaining equity in the company he founded. His ownership stake remains a key factor in Emil Kakkis Net Worth calculations.
When insider transactions occur, they are publicly documented through regulatory filings. These reports allow investors to evaluate executive confidence in company performance. While insider sales have occurred within Ultragenyx, Dr. Kakkis has not been a frequent trader. Long-term retention often signals belief in sustained company value.
Ultragenyx Pharmaceutical Company Overview
Ultragenyx Pharmaceutical Inc. is a biotechnology company focused on developing treatments for rare and ultra-rare genetic diseases. Founded in 2010 by Emil D. Kakkis, the company emphasizes patient-centered development and innovative regulatory strategies. It works to bring life-changing therapies to underserved populations worldwide. The company is publicly traded and headquartered in Novato, California.
Ultragenyx has built a reputation for advancing novel therapies in metabolic and genetic disorders. Its development model challenges traditional clinical endpoints and commercialization approaches. Under Dr. Kakkis’ leadership, the company has expanded its research pipeline significantly. Corporate performance directly influences Emil Kakkis Net Worth due to his substantial stock ownership.
Emil D Kakkis – Net Worth and Insider Trading
Emil D Kakkis – Net Worth and Insider Trading discussions often focus on his dual role as CEO and major shareholder. His wealth is primarily tied to company equity rather than diversified public holdings. Insider trading transparency ensures investors can monitor changes in his ownership. Regulatory compliance plays a key role in maintaining shareholder trust.
As founder of Ultragenyx, his insider status carries influence within the biotech sector. Reports indicate that his trading activity has remained limited in recent periods. Long-term holding strengthens perceptions of executive stability. His financial standing is closely linked to Ultragenyx’s market valuation.
Emil D Kakkis Insider Ownership Reports
Insider ownership reports show that Emil D. Kakkis holds a substantial stake in Ultragenyx Pharmaceutical. These filings are publicly accessible and outline share quantities and transaction details. Insider ownership supports alignment between executive leadership and shareholders. This alignment is often viewed positively by institutional investors.
Ownership disclosures contribute to transparency around Emil Kakkis Net Worth. They help analysts understand how much of the company is controlled by insiders. A 5.5% overall insider ownership figure reflects meaningful executive participation. Strong insider presence can indicate long-term strategic commitment.
Emil D Kakkis Latest Holdings Summary
The latest holdings summary indicates that Dr. Kakkis owns 641,731 shares of Ultragenyx Pharmaceutical stock. The estimated value of these holdings exceeds $13 million based on recent market prices. These shares represent the majority of Emil Kakkis Net Worth. Public filings confirm that no major reduction has occurred recently.
Holdings summaries are updated as transactions are reported to regulators. Investors frequently review these summaries for valuation insights. His continued share ownership demonstrates ongoing engagement with company performance. Stability in holdings often reassures long-term shareholders.
Emil D Kakkis Form 4 Trading Tracker
The Form 4 Trading Tracker provides detailed insights into insider transactions. For Emil D. Kakkis, filings show limited recent trading activity. Form 4 documents are required whenever corporate insiders buy or sell shares. These filings enhance market transparency and investor confidence.
Tracking Form 4 submissions helps evaluate changes affecting Emil Kakkis Net Worth. Consistent ownership levels indicate a steady investment stance. Analysts rely on these trackers to assess insider sentiment. Public reporting ensures accountability in executive share dealings.
Emil D Kakkis Trading Performance
Emil D Kakkis Trading Performance is primarily measured by the long-term appreciation of Ultragenyx stock. Rather than frequent short-term trades, his strategy reflects founder-level commitment. Performance of his holdings depends on company milestones and market conditions. As CEO, his strategic decisions also influence stock movement.
Trading performance is less about volume and more about value growth. Sustained stock ownership suggests alignment with corporate success. Investors monitoring Emil Kakkis Net Worth often compare insider performance with company earnings reports. Long-term equity growth remains central to his financial profile.
Emil D Kakkis Ownership Network
The ownership network of Emil D. Kakkis centers around his executive and board affiliations. As CEO and Director of Ultragenyx Pharmaceutical, he maintains direct influence within the company. He also serves on the board of the EveryLife Foundation for Rare Diseases. His network spans both corporate and nonprofit sectors.
Ownership networks provide insight into professional affiliations and governance roles. These connections highlight his broader impact in rare disease advocacy. While Ultragenyx is his primary financial holding, his leadership influence extends beyond stock ownership. Such networks reinforce his standing in biotechnology leadership.
Ownership Network List of Emil D Kakkis
The ownership network list for Emil D. Kakkis includes Ultragenyx Pharmaceutical and nonprofit board positions. His central executive role establishes direct equity involvement. Board affiliations add governance responsibility but not necessarily equity stakes. Public disclosures focus mainly on Ultragenyx share ownership.
Analyzing ownership lists helps investors understand executive reach and influence. For Emil Kakkis Net Worth, Ultragenyx remains the principal asset. Other affiliations reflect leadership contributions rather than financial diversification. Transparency ensures clarity regarding corporate involvement.
Ownership Network Relation of Emil D Kakkis
Ownership network relations describe how Dr. Kakkis connects to corporate entities through leadership and equity. His strongest relationship remains with Ultragenyx Pharmaceutical as founder and CEO. Additional nonprofit board participation reflects advocacy engagement. These relations expand his professional footprint.
Such network relations can shape industry influence and strategic partnerships. While financial value stems from stock holdings, reputational value extends beyond. Investors view stable ownership relations as a sign of executive dedication. His network supports both mission-driven and commercial objectives.
Emil D Kakkis’s Compensation Overview
Emil D Kakkis’s Compensation Overview highlights an annual base salary of $1,460,000 as CEO. Compensation packages in biotech often include bonuses and equity incentives. His salary contributes significantly to Emil Kakkis Net Worth calculations. Executive compensation aligns with industry standards for public biotech firms.
Beyond salary, equity awards may influence total compensation in certain years. Performance-based incentives can fluctuate depending on company results. Public filings disclose these details annually. Transparent reporting ensures accountability to shareholders and regulators.
Emil D Kakkis Owned Company Details
Emil D Kakkis Owned Company Details primarily reference Ultragenyx Pharmaceutical Inc., the company he founded in 2010. As founder and executive leader, he holds substantial equity. His leadership shaped the company’s patient-focused development model. Ownership reflects both financial stake and operational responsibility.
While he has served in leadership roles at other organizations, Ultragenyx remains his core corporate association. Company growth has directly influenced Emil Kakkis Net Worth over time. His executive tenure underscores long-term strategic involvement. Founder ownership continues to define his financial portfolio.
Ultragenyx Pharmaceutical Inc Insider Transactions
Insider transactions at Ultragenyx Pharmaceutical Inc. include reported buying and selling by executives and directors. Over the past year, insiders collectively sold shares valued at over $5.89 million. Such transactions are disclosed to maintain regulatory transparency. Insider ownership remains around 5.5% of total company shares.
Monitoring insider transactions helps investors gauge executive sentiment. Although sales occurred, insider presence remains meaningful. Emil Kakkis Net Worth remains largely unchanged due to limited recent activity. Public disclosures continue to provide detailed transaction histories.
BioMarin Pharmaceutical Inc Insider Transactions
BioMarin Pharmaceutical Inc. insider transactions are separate from Ultragenyx activity but relevant to Dr. Kakkis’ career history. He previously worked at BioMarin and helped guide rare disease therapy development. However, his current net worth is not primarily tied to BioMarin holdings. Most public wealth data relates to Ultragenyx shares.
Insider reports at BioMarin reflect activities of its current executives and directors. Dr. Kakkis is no longer listed as an active insider there. Historical involvement contributed to his professional reputation. Financial calculations for Emil Kakkis Net Worth focus on present equity ownership.
Emil D Kakkis Mailing Address
The official mailing address for Emil D. Kakkis is:
60 Leveroni Court, Novato, CA 94949. This address corresponds to Ultragenyx Pharmaceutical’s corporate headquarters. Official inquiries regarding executive matters are typically directed here. Investor communications are handled through formal company channels.
Contact details also include the company phone number (415) 483-8800 and investor relations email. Most shareholder or media inquiries go through designated departments. Direct personal correspondence is generally managed by corporate offices. Public contact information ensures professional communication access.
FAQ’s
What is Emil Kakkis Net Worth in 2025?
Emil Kakkis Net Worth is estimated at at least $13.17 million as of March 2025. His wealth mainly comes from his ownership of over 641,000 shares in Ultragenyx Pharmaceutical Inc.. The market value of these shares determines most of his financial standing. His executive salary also contributes to his total net worth.
What is Emil D. Kakkis’ annual salary?
As CEO of Ultragenyx Pharmaceutical, Emil D. Kakkis earns an annual base salary of $1,460,000. In addition to salary, executive compensation packages may include bonuses and stock-based incentives. His earnings reflect leadership responsibilities in a publicly traded biotech company. Compensation disclosures are available through official filings.
How many shares of Ultragenyx does Emil Kakkis own?
Emil D. Kakkis owns approximately 641,731 shares of Ultragenyx Pharmaceutical. These shares form the primary source of Emil Kakkis Net Worth. The value of his holdings changes depending on stock market performance. Public filings confirm his insider ownership position.
Has Emil D. Kakkis recently traded Ultragenyx stock?
Recent disclosures indicate that Dr. Kakkis has not been actively trading shares in the last ninety days. His trading history shows a long-term holding strategy rather than frequent buying or selling. Insider trading data is publicly available through SEC Form 4 filings. This transparency allows investors to monitor executive share activity.
What company did Emil D. Kakkis found?
Emil D. Kakkis founded Ultragenyx Pharmaceutical Inc. in 2010. The company focuses on developing therapies for rare and ultra-rare genetic diseases. His leadership emphasizes patient-centered development and regulatory innovation. Ultragenyx remains the core driver behind Emil Kakkis Net Worth and professional legacy.
Conclusion
Emil Kakkis Net Worth reflects decades of leadership in biotechnology and rare disease innovation. As founder and CEO of Ultragenyx Pharmaceutical Inc., his wealth is largely tied to substantial stock ownership and executive compensation. With an estimated net worth exceeding $13 million and a $1.46 million annual salary, his financial profile aligns closely with company performance.
Beyond numbers, Dr. Kakkis’ career demonstrates a commitment to advancing treatments for rare genetic disorders. His insider ownership, steady trading history, and executive leadership position reinforce long-term confidence in Ultragenyx’s mission. Ultimately, Emil Kakkis Net Worth represents not only financial success but also sustained impact in the biotech industry.
